SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. “Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results fro ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CARNK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment Conference Format: Prese ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from _______ to _______ Commission File Number 001-40440 _________________________ Senti Bioscie ...

Financial Performance - Senti Bio reported a net loss of $11.2 million for Q2 2024, compared to $18.7 million in the same period in 2023[4][10] - Cash and cash equivalents stood at $15.9 million as of June 30, 2024, down from $35.9 million at the end of 2023[4][9] - Total assets decreased to $86.9 million as of June 30, 2024, from $119.5 million at the end of 2023[9] Research and Development (R&D) - R&D expenses increased to $9.2 million in Q2 2024, up from $6.9 million in Q2 2023, primarily due to manufacturing costs for wholly-owned programs[4][10] - Senti Bio received an $8 million grant from CIRM to support the clinical development of SENTI-202 for relapsed/refractory hematologic malignancies[2] - Patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for AML, with initial efficacy data expected by year-end 2024[3] - Senti Bio plans to initiate a pilot trial of SENTI-301A for hepatocellular carcinoma in China through a partnership with Celest, with first patient dosing expected in Q4 2024[3] General and Administrative (G&A) Expenses - G&A expenses decreased to $4.2 million in Q2 2024, down from $9.2 million in Q2 2023, mainly due to a reduction in headcount[4][10] Corporate Actions - The company effected a 1-for-10 reverse stock split in July 2024 to comply with Nasdaq's minimum bid price requirement[3] Receivables and Transactions - Senti Bio anticipates $18.9 million in receivables from the GeneFab transaction upon satisfaction of certain conditions[4]

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported fina ...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant wil ...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant wil ...

Forward-Looking Statements This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended including statements with respect to Senti Bio's ability to regain compliance with Nasdaq's continued listing standards and remain listed on Nasdaq or any other major stock exchange and other statements that are forwar ...

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio") , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a onefor-ten (1-for-10) reverse stock split of Senti Bio's common stock, par value $0.0001 per share (the "Common Stock"). The reverse stock split will take effect at 11:59 p.m. EDT on July 17, 2024, and S ...

"On behalf of the Senti Bio team, I'd like to express our sincere gratitude to CIRM for its support of our Phase 1 trial of SENTI-202 and for recognizing SENTI-202's potential to improve the lives of people living with AML," said Timothy Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Bio. "We are proud of the clinical development progress to date as the Phase 1 trial continues to enroll and will remain steadfast in our mission to provide potentially lifesaving treatments for people living ...